Class: GI function test
- Injection, lyophilized powder for solution 16 mcg
- Injection, lyophilized powder for solution 40 mcg
Increase the volume and bicarbonate content of secreted pancreatic juices.
Vd is 2.7 L.
Cl is 580.9 ± 51.3 mL/min. After IV bolus administration of 0.4 mcg/kg, plasma concentration rapidly declines to baseline secretin levels within 90 to 120 min. Elimination half-life is 45 min.
Indications and Usage
Stimulation of pancreatic secretions, including bicarbonate, to aid in diagnosis of pancreatic exocrine dysfunction; stimulation of gastrin secretion to aid in diagnosis of gastrinoma; stimulation of pancreatic secretions to facilitate the identification of ampulla of Vater and accessory papilla during endoscopic retrograde cholangiopancreatography.
Dosage and AdministrationStimulation of Gastrin Secretion
IV 0.4 mcg/kg over 1 min.Stimulate Pancreatic Secretions; Facilitation of Identification of Ampulla of Vater
IV 0.2 mcg/kg over 1 min.
- For IV administration only. Not for intradermal, subcutaneous, IM, or intra-arterial administration.
- Reconstitute powder using sodium chloride injection following manufacturer's instructions. Shake vigorously to dissolve. Each mL of reconstituted solution contains secretin 2 mcg.
- Use immediately after reconstitution. Discard any unused portion.
Store vials in freezer (−4°F). Protect from light.
May make patient hyporesponsive, producing false-positive results.
Laboratory Test Interactions
None well documented.
Hypotension, increased heart rate, slow heart rate.
Anxiety, faintness, sedation.
Clammy skin, flushing.
Diarrhea, increased oral secretions, mild pancreatitis, nausea, upset stomach, vomiting.
Abdominal pain, burning sensation in abdomen or stomach, decreased O 2 saturation, early removal of Dreiling tube, tingling in legs, unresponsiveness, warm sensation in abdomen, warm sensation in face.
Safety and efficacy not established.
Differences in responses between elderly and younger patients have not been identified, but greater sensitivity cannot be ruled out.
Patients who have alcoholic or other liver disease may have a greater than normal volume response to secretin stimulation; interpret results of secretin stimulation tests with caution.
Do not administer to patient with acute pancreatitis until the episode has resolved.
Because of potential allergic reaction, patients should receive an IV test dose of 0.2 mcg (0.1 mL).
Inflammatory bowel disease or vagotomy
Patients who have inflammatory bowel disease or who have undergone vagotomy may be hyporesponsive to secretin stimulation. This does not indicate pancreatic disease; interpret results of secretin stimulation tests with caution.
No data available.
- Explain name, action, and potential side effects of drug, and how drug will be used during the specific procedure that is going to be performed.
- Advise patient that medication will be prepared and administered by a health care provider in a medical setting.
Copyright © 2009 Wolters Kluwer Health.